A Phase II Randomized Study of Docetaxel With or Without NINTEDANIB (BIBF-1120) in Patient Receiving a Second-line of Chemotherapy for HER Negative Metastatic or Locally Recurrent Breast Cancer

Trial Profile

A Phase II Randomized Study of Docetaxel With or Without NINTEDANIB (BIBF-1120) in Patient Receiving a Second-line of Chemotherapy for HER Negative Metastatic or Locally Recurrent Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Nintedanib (Primary) ; Docetaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms VAROCE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 03 Nov 2015 Planned number of patients changed from 220 to 252, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top